Lixte Biotechnology Holdings Inc — Cash Flow (NASDAQ:LIXT) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Cash from operating activities 2.13 M-4.14 M-4.61 M-4.29 M-3.16 M -2.58 M Cash from investing activities ————— — Cash from financing activities 4.6 M3.9 M5.14 M3.14 M0 6.47 M Free cash flow 2.13 M-4.14 M-4.61 M-4.29 M-3.16 M -2.58 M

News

LIXTE Biotechnology appoints Sidney Braun to lead Liora subsidiary

LIXTE expands clinical trial for ovarian cancer treatment

Lixte Biotechnology stock falls after $4.3 million direct offering

Spartan Capital acts as placement agent in Lixte’s $4.3 million offering

Lixte Biotechnology stock falls after $4.3 million direct offering

Lixte Biotechnology raises $4.3 million in registered direct offering

Lixte Biotechnology shareholders approve board nominees and stock plan amendment

Lixte Biotechnology stock falls after acquiring UK-based Liora

LIXTE Biotechnology acquires UK-based proton therapy developer Liora

Earlyworks shareholders reject share issuance for acquisition, approve new directors and warrants

BOCA RATON - Lixte Biotechnology refreshes leadership and diversifies assets

LIXTE Biotechnology announces leadership changes and $5 million funding